Literature DB >> 1122681

Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype.

T P Gibson, J Matusik, E Matusik, H A Nelson, J Wilkinson, W A Briggs.   

Abstract

To assess the extent of the acetylation of procainamide (PA) to N-acetylprocainamide (NAPA) in man, and its relation to isonicotinic acid hydrazide (INH) acetylation phenotype, the following study was done. Fourteen subjects received 500 mg of PA - HCL orally. INH acetylation phenotype was determined by the serum half-life of INH after 4 mg/kg of INH orally. Each urine voided for 96 hr after procainamide was saved and levels of procainamide and NAPA measured by gas-liquid chromatography. The 14 subjects eliminated 52 plus or minus 4 percent of the dose as procainamide and 16 plus or minus 2 percent of the dose as NAPA. Four fast INH acetylators eliminated 23 plus or minus 3 percent of the dose as NAPA compared to 12 plus or minus 1 percent by the slow acetylators (p smaller than 0.05). The amount of unaltered procainamide excreted by the fast and slow INH acetylators was not significantly different, 50 plus or minus 4 percent and 53 plus or minus 4 percent, respectively. Of the total amount of drug recovered in the urine of the fast and slow INH acetylators, NAPA accounted for 32 percent and 19 percent, respectively (p smaller than 0.01). There appears to be a positive correlation between the ability to acetylate INH and the ability to acetylate procainamide.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1122681     DOI: 10.1002/cpt1975174395

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status.

Authors:  R Latini; A P Maggioni; A Cavalli
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Pharmacokinetics of sulphamethoxazole in man: effects of urinary pH and urine flow on metabolism and renal excretion of sulphamethoxazole and its metabolite N4-acetylsulphamethoxazole.

Authors:  T B Vree; Y A Hekster; A M Baars; J E Damsma; E van der Kleijn
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

3.  Acetylator phenotype and the clinical pharmacology of slow-release procainamide.

Authors:  W Campbell; W J Tilstone; D H Lawson; I Hutton; T D Lawrie
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

4.  The relationship between the acetylator and the sparteine hydroxylation polymorphisms.

Authors:  D Harmer; D A Evans; L C Eze; M Jolly; E J Whibley
Journal:  J Med Genet       Date:  1986-04       Impact factor: 6.318

5.  Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.

Authors:  J J Lima; D R Conti; A L Goldfarb; W J Tilstone; L H Golden; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

6.  Comparison of the acetylation of procainamide and sulfadimidine in man.

Authors:  K Frislid; M Berg; V Hansteen; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

7.  A pharmacokinetic comparison of two sustained-release oral procainamide preparations.

Authors:  P Hore; P Bones; T Rollinson; H Ikram
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

Review 8.  Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.

Authors:  D E Drayer
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of procainamide.

Authors:  E Karlsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

10.  Polymorphic acetylation of sulphadimidine in normal and uraemic man.

Authors:  T Talseth; K H Landmark
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.